Navigation Links
Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
Date:6/1/2009

e rates of 30% in this population of patients would represent a significant advance in the treatment of aggressive NHL and commented that that while numerically higher, the overall incidence of cardiac events were lower than expected in this patient group with substantial prior doxorubicin exposure reflected by no significant change in ejection fraction from baseline to end of treatment.

"This data demonstrates that pixantrone can induce durable complete remissions not only in patients previously treated with standard front-line doxorubicin, but even in patients who received an anthracycline as part of a salvage regimen. Resistance to rituximab was not associated with resistance to pixantrone. In patients with high cumulative prior doxorubicin exposure, the frequency of severe cardiac toxicity following up to six cycles of additional pixantrone was lower than would be expected based on historical comparisons to studies of doxorubicin," said James A. Bianco, M.D., Chief Executive Officer of CTI. "We are pleased with these results as they underscore the potential for pixantrone in this difficult to treat patient population for whom few options exist."

About the PIX301 EXTEND Trial

The PIX 301 EXTEND clinical trial was a phase III single-agent trial of pixantrone for patients with relapsed or refractory, aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician.

CTI previously announced that its pivotal phase III EXTEND (PIX 301) trial of pixantrone had achieved its primary endpoint with patients randomized to treatment with pixantrone achieving a significantly higher rate of confirmed (CR) and unconfirmed complete remissions (CRu)
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
2. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
3. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
4. Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkins Lymphoma Trial
5. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
6. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
7. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
8. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
9. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
10. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
11. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)...   BioLife Solutions , Inc. (NASDAQ: BLFS ), ... cell and tissue hypothermic storage and cryopreservation ... cold chain management app for smart shippers ... Magazine has included BioLife in its annual list of ... Washington state for 2015. Now in ...
(Date:7/2/2015)... 2, 2015 Legal-Bay LLC, The Lawsuit Settlement ... Joseph Goodwin in the Southern District of ... mesh cases against Ethicon for a single trial to ... for the 26 women include claims from the women ... my Johnson & Johnson,s Ethicon subsidiary. The cases against ...
(Date:7/1/2015)... , July 1, 2015 The Coalition ... of state and regional professional rheumatology societies, today ... rheumatologists that explored perceptions of biosimilars and the ... Biosimilars are medicines that are ... They are notably different from generic medications in ...
Breaking Medicine Technology:BioLife Solutions Named One of the 100 Best Companies to Work For in Washington State 2BioLife Solutions Named One of the 100 Best Companies to Work For in Washington State 3Judge Sets Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 2Judge Sets Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 3Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2
... N.J., Sept. 20 Princeton HealthCare System (PHCS) ( www.princetonhcs.org ... October 4, when it hosts a discussion about women,s pelvic ... program begins at 7 p.m. and can be joined by ... "Social media has enormous potential for sharing information ...
... and plant closure, the company still outpaces Advil in ... released today. The study showed that ... the same way they instinctively perceive and judge other ... and these judgments are highly predictive of brand purchase ...
Cached Medicine Technology:First Live Web Chat by New Jersey's Princeton HealthCare System Focuses on Women's Health 2Study of Brands Shows Tylenol Maintains Consumer Loyalty Despite Recent Quality Challenges 2
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ... and Emerging Healthcare Delivery Coalition met for the late June Web-based session, the ... with new reimbursement schemes and managing high-risk patients through coordinated care. , During ...
(Date:7/2/2015)... Beach, CA (PRWEB) , ... July 02, 2015 ... ... surgical procedures and executing them with care and precision. There is an art ... FAACS, has had the honor of successfully reshaping the facial features and lives ...
(Date:7/2/2015)... , ... July 02, 2015 , ... ... (CVR) recently received nearly $4 million through five federal grants to study ... and therapies against the deadly diseases. , The research will be conducted ...
(Date:7/2/2015)... ... 02, 2015 , ... B. E. Smith, the only full-service ... a national chief executive officer recruitment for Indiana Blood Center in ... B. E. Smith has recently placed more than 1,000 healthcare executives into organizations. ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... of the Gelatin Capsule manufacturers. The report is a valuable source of guidance ... depicts the global and Chinese market for the Gelatin Capsule industry including capacity, ...
Breaking Medicine News(10 mins):Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 2Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 3Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 4Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 2Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 3Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 2Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 3Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 4Health News:Indiana Blood Center Retains B. E. Smith to Recruit New Chief Executive Officer 2Health News:Indiana Blood Center Retains B. E. Smith to Recruit New Chief Executive Officer 3Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 2Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 3Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 4
... When it comes to the attractiveness of orthodontic braces, ... The study of the public,s attitude about the attractiveness of ... appliances with no visible metal were considered the most attractive. ... clear wires were a less desirable option, and braces with ...
... WEDNESDAY, July 9 (HealthDay News) -- Being born extremely underweight ... as an adult. , A study published in the July ... were born at extremely low birth weights were more likely ... had been born at normal weights. , And that ...
... Reaches Out to Patients in Need of ... Care ... DaVita,Medical Missions(TM), a non-profit organization founded by DaVita Inc. that,focuses on bringing ... clinic in India in late,June. The new clinic is located in the ...
... U.S. Senate to vote soon on legislation that ... Minnesota, WASHINGTON, July 9 Seniors across ... Medicare Advantage program in,legislation being considered in the ... million from the Medicare Advantage program in,Minnesota alone ...
... the U.S. Senate,prepares to vote on legislation that would ... (AMA) is calling on Senators,to cast a yes vote ... In,June, the House passed the Medicare Improvements for Patients ... bipartisan vote of 355 to 59., "Last week, ...
... matinee, throughout U.S.,to debut film targeting Lazard CEO, ... residents from,controversial assisted living provider Atria Senior Living ... Thursday in a "rolling,matinee" to debut a new ... Films about Atria,s mistreatment of its workers and,elderly ...
Cached Medicine News:Health News:Survey: Most effective dental braces are least attractive 2Health News:Survey: Most effective dental braces are least attractive 3Health News:Do Underweight Newborns Make for Shy Adults? 2Health News:U.S. Non-Profit Brings Life-Saving Dialysis Treatment to India 2Health News:U.S. Non-Profit Brings Life-Saving Dialysis Treatment to India 3Health News:Minnesota Seniors Speak Out Against Medicare Advantage Cuts 2Health News:New Film Exposes Bruce Wasserstein and Lazard-linked Elderly Care Facilities Exploiting Seniors 2
... Articulating Tip Laryngoscopes are the ... Industry. The articulating tip aids ... an improved view of epiglottis. ... Optic styles. We guarantee your ...
CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
Medicine Products: